Topic Archives: immunotherapy

There’s a clear winner in the “what readers are asking about” sweepstakes this morning, and it’s the latest pitch from Charles Mizrahi for his Park Avenue Investment Club (currently $99/yr) — so that ad must really be making the rounds, and we’ll fire up the Thinkolator to get you some answers today. The pitch is […]

This is a combo you don’t hear about very often, “founded in the 17th century” and “cancer killing blockbuster” … usually, the little biotechs that newsletters drop hints about are tiny, young, risky, sometimes fly-by-night outfits that are betting it all on a clinical breakthrough. Not this time, apparently. So that’s why my eye was […]

Another biotech teaser for you today — these never seem to stop, perhaps partly because small biotech stocks are almost the only ones, other than little junior miners, that have a legitimate chance of seeing their prospects change dramatically overnight or see rapid 100%, 200%, 500% share price gains on a new discovery or shockingly […]

Comments

  • Avatar

    Sounds very promising. Almost like an Immunotherapy Cancer Stock called CEL-SCI Ticker CVM $14.49 Completed Phase III ...

  • Avatar

    Yes the covid-19 vaccine race is definitely a bubble similar to the latest weed bubble not too long ago. However, if I ...

  • Avatar

    Here is a summary of vaccines and medications for symptoms companies associated: Clinical trials: Drug/Treatment: R...

  • Avatar

    I was hoping that you were going to reveal the company that Stansberry says has found a cure for cancer by using immunot...

  • SoGiAm

    $XCUR calendar of upcoming events: http://investors.exicuretx.com/phoenix.zhtml?c=254193&p=irol-calendar Upcoming ...

  • SoGiAm

    #History > Immunotherapy: Revolutionizing Cancer Treatment since 1891 https://www.mskcc.org/blog/immunotherapy-revoluti...

  • Avatar

    I like MRK and PFE for the next 12 months in my steady as she goes account.But, for big potential I am in the speculativ...

  • Michael Jorrin,

    That depends on what you mean by "movers and shakers." I try to keep abreast of what's going on in the research areas ...

  • SoGiAm

    New approach to #immunotherapy leads to complete response in bre ast cancer patient https://medicalxpress.com/news/201...

  • Avatar

    The most beneficial cellular targets will be cell-types that regularly divide. This includes epithelium, or surface tiss...

  • SoGiAm

    $Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Pr...

  • SoGiAm

    $CLLS, $PFE 20183018-21 > Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the ...

  • SoGiAm

    Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells https://www.nature.com/...

  • SoGiAm

    $BGNE has a new IDO1 inhibitor (BGB-5777) that they are claiming has greater BBB penetration than the $INCY compound. He...

  • SoGiAm

    $$HTBX fp - #OpposableThumb a forward? say 3:1 :-) *UPDATE: Heat Biologics Says 'Overall responses appeared durabl...

  • SoGiAm

    #SRNE ow - Restated financials for NANT investment ed to changes for impaimetn charge: The number of shares of the iss...

  • SoGiAm

    Keep the $FATE :-) February 23, 2018 8:00 AM EST Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Transl...

  • Avatar

    $PIRS np Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th BOSTON, MA--(Marketwired - J...

  • Avatar

    SRNE-NP- company Doc talked fondly of yesterday and former shareholder. Lurking with this company with its leading antib...

  • Avatar

    $ONCS - long I still own ONCS. I'm very interested in hearing more of the bear argument. In truth, I'm low on portfo...

  • Avatar

    $SRNE Long From January 16th Sorrento Therapeutics target raised to $30 at H.C. Wainwright -- Multiple Recent De...

  • DrKSSMDPhD

    Trading notices: Exit $DFFN.....had starter position, but don't feel company holding up under due diligence Exit $...

  • Avatar

    $ATNM long tyler_l45. So with CAR-T, it is antibody specific also. I am pasting from a cancer network website -"Ultim...

  • Avatar

    $INO UW Inovio and Parker Institute announce clinical collaboration agreement Inovio Pharmaceuticals and the Parker...

  • Avatar

    I wonder if these comments are from the real Myron Martin or an impostor. I say that because I believe that I have read...

  • DrKSSMDPhD

    I have been on the phone with them today trying to arrange a time to visit corp HQ. Working on it. This is a very intell...

  • SoGiAm

    $AFMD fp - (long) Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Comple...

  • SoGiAm

    #Moderation Please! $FATE long – Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells fro...

  • SoGiAm

    $FATE long - Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells from Clonal Engineered Ma...

  • SoGiAm

    The cancer immunotherapy pipeline is overcrowded; $SAGE, Roche $RHBBY, Spark $ONCE tout big advances https://endpts.co...

  • SoGiAm

    $BIOC - Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept'...

  • SoGiAm

    $CLLS long - Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adop...

  • Avatar

    $ONCS PBS News Hour Cancer Immunotherapy has Life Saving Powers and Limits https://www.pbs.org/newshour/show/cancer-immu...

  • Travis Johnson, Stock Gumshoe

    There's a lot of work being done to combine immunotherapy with radiation therapy, as well, with some real promise, from ...

  • Avatar

    I was hoping that the company mentioned would be doing something with immunotherapy. Instead of some machine frying me ...

  • Avatar

    $STML LONG NEW YORK, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage b...

  • Avatar

    ONCS (long as of yesterday) nice interview with CEO. First impression from his interview and body language is that he fe...

  • Avatar

    $TRIL Long Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developin...

  • SoGiAm

    $SNDX - Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Im...

  • SoGiAm

    $HTBX np - Heat Biologics Presents Follow-up Data on its ComPACT™ T-cell Stimulating Platform at the Society for Immun...

  • Avatar

    $ONCS LONG Dr. Alain Algazi will present the updated data in an oral poster presentation (P524) at the Society for I...

  • Avatar

    $ONCS LONG 10-Nov-17 Conferences SITC 32nd Annual Meeting Society for Immunotherapy of Cancer 2017 (ONCS...

  • Avatar

    $ONCS OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer I...

  • Avatar

    $ONCS LONG .com: OncoSec to present results of multi-gene expression platorm at SITC meeting OncoSec Medical will p...

  • Avatar

    Doc, would not the great data yesterday from ONCS bold well for HTBX with their partnership with them to combine their i...

  • Avatar

    $ONCS - new publication “Restoration of natural killer cell anti-metastatic activity by IL-12 and checkpoint block...

  • Avatar

    $RXDX Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer...

  • Avatar

    $ONCS Analyst Event in National Harbor, MD OncoSec will host an analyst and investor event with clinical investigator...

  • Avatar

    $ONCS NP Have been looking at this all morning and was just going to ask you Doc, your take on it. OncoSec r...

  • Avatar

    $SNDX LONG More News 07-Nov-2017:08:00:00, Syndax to Present at the SITC 32nd Annual Scientific Meeting WAL...

  • SoGiAm

    $HTBX - November 11th, 17 - Heat Biologics to Present Data on its ComPACT Technology, at the Society for Immunotherapy o...

  • Avatar

    $TRIL Trillium Therapeutics to Present at Upcoming Scientific Conferences (5 presentations!!! November 6, 2017 ...

  • Avatar

    $Probiotic $Immunotherapy $Melanoma **A new MD Anderson study (11/3) “Tuning the Microbiome Improves Melanoma...

  • SoGiAm

    $FATE - Fate Therapeutics Announces Six Presentations At The 2017 ASH Annual Meeting Fate Therapeutics Reports Third ...

  • SoGiAm

    $PIRS and $AFMD - October 31st, 2017: Both companies present at the World Immunotherapy Congress in Basel. Both presen...

  • SoGiAm

    $CLRB and Z long - Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in...

  • Avatar

    $ HALO LONG Halozyme Therapeutics (HALO) announces the initiation of a multi-arm clinical trial evaluating PEGPH20,...

  • SoGiAm

    $HALO - Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder ...

  • DrKSSMDPhD

    I'm coming to you live from the MicroCap Conference at Essex House near Central Park. I just had a fascinating conver...

  • SoGiAm

    $capr dmd. Poster link MIA. 6mo PUL MIA. https://twitter.com/XsleepftLearner/status/915540626602590208 $CNCR Lonca...

  • SoGiAm

    $RXDX np - Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology ...

  • Avatar

    $Noticker. Interesting "puff piece" on influential husband/wife MD Anderson researchers in immunotherapy, one of whom p...

  • SoGiAm

    $TRIL - Novemberf 8- 12, 17 - Society for Immunotherapy of Cancer 32nd Annual Meeting in National Harbour, MD http://...

  • Avatar

    $ARGS-Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017...

  • Avatar

    $FATE Coverage resumed by Leerink with PT=$7 Fate Therapeutics resumed with an Outperform at Leerink Leerink anal...

  • Avatar

    $ARGS Press Release yesterday, September 6, 2017 Argos Announces First Dosing of HIV Patient with AGS-004 Derived fro...

  • Avatar

    https://globenewswire.com/news-release/2017/08/21/1090597/0/en/Argos-Therapeutics-Announces-Interim-Analysis-of-Phase-3-...

  • SoGiAm

    Unum Therapeutics - private - to Present at Wedbush PacGrow Healthcare Conference August 14, 2017 08:00 AM Eastern Day...

  • Avatar

    Immunotherapy treatment for Type 1 Diabetes. http://www.cbsnews.com/news/immunotherapy-treatment-shown-safe-in-type-1...

  • SoGiAm

    Identification of essential genes for cancer immunotherapy http://www.nature.com/nature/journal/vaop/ncurrent/full/natu...

  • Avatar

    $ Beat Melanoma Wanted to share that after two years of treatment, a family member’s melanoma lesions in her leg hav...

  • SoGiAm

    $HALO np - Halozyme Therapeutics has added a new press release to its web site. For full details please visit the Halozy...

  • Avatar

    $CLRB Hello Doc, I saw you musing on twitter recently about a potential application for Cellectar's phospholipid e...

  • Avatar

    $AFMD New publication on Affimed's TandAb (AFM-13)): a first-in-class tetravalent bispecific anti-CD30/CD16A antibody...

  • Avatar

    Dr. KSS - here's is what I know on my friend, Nabeel Qureshi's current status and treatment at MD Anderson. He was told ...

  • Avatar

    Good listen on overcoming immunotherapy resistance. http://noveltargets.com/2017/05/episode-17-overcoming-immunotherapy...

  • Avatar

    I belong to a group of fans that reads and suggests changes to novels of Mark Dawson, a British writer of 007 type ficti...

  • SoGiAm

    $FATE - June 4th - Fate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research wit...

  • SoGiAm

    $FATE long - Fate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-...

  • Anamorph

    Magbio: welcome to the Gummune. Good research and questions. I did a great deal of homework on Dhillon back in 201...

  • Avatar

    $BLRX -small long position From a March 27th news release: BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage bi...

  • Avatar

    $BLRX-NP JMP note: BioLineRx Ltd. (BLRX: $1.09; $64.5M market cap ) BioLineRx reports 4Q16 earnings results and the ac...

  • SoGiAm

    $FATE long - $FATE Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Ca...

  • SoGiAm

    $FATE - Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the...

  • SoGiAm

    $FATE long - Fate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Tra...

  • DrKSSMDPhD

    Thanks Scorpio for noting that for sicilia. I would add someone was commenting yesterday that of our recent long ideas, ...

  • DrKSSMDPhD

    $KITE will be first to FDA with BLA filing for CAR-T indication, but surprisingly Novartis is right on their heels: htt...

  • Avatar

    FYI - Immunotherapy biotech Jounce Therapeutics sets terms for $75 million IPO 1/17/17 Jounce Therapeutics, an ear...

  • Avatar

    $KITE long CAR T-Cell Therapy for Lymphoma Leads to Complete Remission in Phase I Trial Immunotherapy approaches ...

  • Avatar

    Regarding PTN ---one should look at other transactions---cannot ignore management and financial considerations 1) MEI...

  • Avatar

    Nice article on immunotherapy http://www.bionapcfa.com/2017/01/a-look-at-cancer-immunotherapy-and-some.html $BMY ...

  • Avatar

    To All, Someone posted yesterday that Fortress Bio, symbol FBIO, had success with CAR T cell immunotherapy, is that si...

  • Avatar

    Anecdotal evidence m of FBIO (fortress bio) treatment using genetically modified Car-T immunotherapy (stock up pre-marke...

  • DrKSSMDPhD

    Hi savinir: Welcome to Gumtown, and good of you to ask about these stocks. $HTBX is a firm local for me and one about...

  • SoGiAm

    oNKo-innate Retweeted Marseille Immunopole ‏@Immunopole 2h2 hours ago Combination in #cancerimmunotherapy: obviou...

  • Avatar

    A current Neeswek article on #KRAS in cancer immunotherapy TRACKING DOWN ONE OF CANCER'S DEADLIEST CULPRITS, THE RAS...

  • Avatar

    #KRAS #TILS #Immunotherapy: Original article in NEJM which the prior NYT article was based on. T-Cell Transfer Therap...

  • Avatar

    First successful case of Immunotherapy targeting #KRAS #TILs **1 Patient, 7 Tumors and 100 Billion Cells Equal 1 Str...

  • Avatar

    For a while $TRIL was my largest position. I sold much of it after “FortySeven” (aka Stanford University) presented...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info